ロード中...

AXL mediates resistance to cetuximab therapy

The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical problem. In this study we show that overexpression of the oncogenic receptor kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-s...

詳細記述

保存先:
書誌詳細
主要な著者: Brand, Toni M., Iida, Mari, Stein, Andrew P., Corrigan, Kelsey L., Braverman, Cara, Luthar, Neha, Toulany, Mahmoud, Gill, Parkash S., Salgia, Ravi, Kimple, Randall J., Wheeler, Deric L.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4167493/
https://ncbi.nlm.nih.gov/pubmed/25136066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-0294
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!